XENE - Xenon Pharmaceuticals Inc.
IEX Last Trade
40.12
0 0%
Share volume: 20,503
Last Updated: Tue 24 Dec 2024 03:31:02 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.45%
PREVIOUS CLOSE
CHG
CHG%
$40.12
-2.13
0.06%
Fundamental analysis
15%
Profitability
8%
Dept financing
2%
Liquidity
75%
Performance
10%
Performance
5 Days
-1.83%
1 Month
-7.32%
3 Months
-2.57%
6 Months
3.26%
1 Year
-13.44%
2 Year
1.44%
Key data
Stock price
$40.12
DAY RANGE
$37.61 - $38.44
52 WEEK RANGE
$36.84 - $50.99
52 WEEK CHANGE
-$13.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Ian C. Mortimer
Region: US
Website: xenon-pharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: xenon-pharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.
Recent news